Gland Pharma Ltd. (GLAND) AI Stock Analysis

• Market Cap: ₹318.91B
• Dividend Yield: 0.94%
• Average Volume (3M): 9.08K
• Price to Earnings (P/E): 41.4
• Beta (1Y): 0.51
• Revenue Growth: -2.34%
• EPS Growth: 6.64%
• Country: IN
• Employees: 4,217
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 13.08
• Shares Outstanding: 164,756,420
• 10 Day Avg. Volume: 10,062
• 30 Day Avg. Volume: 9,084
• PEG Ratio: -3.82
• Price to Book (P/B): 2.80
• Price to Sales (P/S): 4.56
• P/FCF Ratio: 48.27
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,973.75
• Price Target Upside: 3.75% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

• Rating: 66 Neutral
• Price Target: ₹2,092.00 ▲(9.96% Upside)

Gland Pharma Ltd. demonstrates strong financial performance, which is the most significant factor supporting its stock score. However, technical indicators suggest weak market momentum, and the high P/E ratio indicates potential overvaluation. The absence of earnings call data and corporate events limits additional insights.

Gland Pharma Ltd. Business Overview & Revenue Model

Company Description

Gland Pharma Ltd. (GLAND) is a leading Indian pharmaceutical company specializing in the development, manufacturing, and marketing of complex injectables and other pharmaceutical products. With a strong focus on generic formulations, GLAND operates in various therapeutic segments including oncology, anesthesia, and cardiovascular care. The company is known for its high-quality products and robust manufacturing capabilities, which are complemented by its commitment to research and development.

How the Company Makes Money

Gland Pharma generates revenue primarily through the sale of its pharmaceutical products, particularly its complex injectables, which are sold in both domestic and international markets. The company's revenue model is driven by multiple key streams, including direct sales to hospitals and healthcare providers, partnerships with global pharmaceutical companies for product distribution, and licensing agreements for its proprietary formulations. Additionally, Gland Pharma benefits from economies of scale due to its extensive manufacturing facilities, which allow for cost-effective production. Significant partnerships with international firms enhance its market reach and contribute to steady revenue growth.

Gland Pharma Ltd. Financial Statement Overview

Summary

Gland Pharma Ltd. exhibits strong financial health with consistent revenue growth, solid profitability metrics, and a strong balance sheet. The company maintains efficient cash flow management, although recent declines in net income and free cash flow growth require careful attention.

Income Statement

Gland Pharma Ltd. has shown consistent revenue growth over the years, although there was a slight dip in 2025. The company maintains strong gross and net profit margins, with EBIT and EBITDA margins indicating efficient operational management. However, the recent decline in net income may point to potential challenges in maintaining profit margins.

Balance Sheet

The company demonstrates a robust balance sheet with a strong equity base and a low debt-to-equity ratio, indicating low financial leverage and risk. The equity ratio is solid, reflecting financial stability and a healthy capital structure. However, the slight increase in total liabilities over the years requires monitoring.

Cash Flow

Operating cash flow remains strong, supporting the company's ability to fund operations. The free cash flow is positive, though it has shown some fluctuations. The cash flow ratios suggest efficient cash management, yet the decrease in free cash flow growth rate in recent years could indicate challenges in cash generation.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	57.20B	56.17B	56.65B	36.25B	44.01B	34.63B
Gross Profit	33.02B	31.54B	31.11B	17.65B	21.51B	18.53B
EBITDA	13.20B	12.31B	12.97B	10.31B	15.10B	13.02B
Net Income	7.70B	6.99B	7.72B	7.81B	12.12B	9.97B
Balance Sheet
Total Assets	0.00	112.25B	106.61B	87.78B	78.34B	64.96B
Cash, Cash Equivalents and Short-Term Investments	29.52B	29.52B	19.39B	37.63B	32.43B	30.03B
Total Debt	0.00	3.14B	3.72B	44.53M	47.43M	49.95M
Total Liabilities	-91.51B	20.74B	19.37B	8.19B	6.76B	5.93B
Stockholders Equity	91.51B	91.51B	87.24B	79.59B	71.58B	59.03B
Cash Flow
Free Cash Flow	0.00	5.30B	6.07B	1.41B	2.69B	3.76B
Operating Cash Flow	0.00	9.15B	9.97B	3.64B	7.91B	6.05B
Investing Cash Flow	0.00	17.05B	-17.57B	12.08B	-10.03B	-15.24B
Financing Cash Flow	0.00	-4.33B	-7.99B	149.19M	348.98M	12.38B

Gland Pharma Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1902.50
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GLAND, the sentiment is Neutral. The current price of 1902.5 is below the 20-day moving average (MA) of 1941.47, below the 50-day MA of 1945.38, and above the 200-day MA of 1711.21, indicating a neutral trend. The MACD of -10.73 indicates Positive momentum. The RSI at 40.36 is Neutral, neither overbought nor oversold. The STOCH value of 36.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:GLAND.

Gland Pharma Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	―	₹630.26B	18.58	―	0.36%	7.76%	-2.84%
DRREDDY	―	₹1.05T	18.44	―	0.64%	14.10%	9.72%
SUNPHARMA	―	₹4.05T	38.84	―	0.95%	9.28%	-0.17%
GLAND	―	₹318.91B	41.40	―	0.94%	-2.34%	6.64%
TORNTPHARM	―	₹1.22T	60.49	―	0.89%	7.63%	15.39%
GLAXO	―	₹465.11B	48.87	―	2.04%	6.65%	48.47%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Gland Pharma Ltd. Corporate Events

Gland Pharma Appoints New Secretarial Auditors to Strengthen Governance

Gland Pharma Limited has announced the appointment of M/s. RVR & Associates as the Secretarial Auditors for a term of five years, following approval at the company’s 47th Annual General Meeting. This strategic appointment is expected to enhance the company’s compliance management and corporate governance, potentially strengthening its market position and stakeholder confidence.